Alzheimer’s Drug Discovery Foundation – Drug Development Program | Research Funding
Event details
| Date | 30.09.2022 |
| Category | Call for proposal |
Aim: The Drug Development RFP seeks to support in vivo preclinical studies that advance lead molecules developed for Alzheimer’s disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application.
Specifically, the Drug Development RFP supports the following stages of discovery:
Current target areas of interest include:
Funding: max. $600,000
Duration: 1 year
Eligibility: Funding is open to researchers and clinicians worldwide at academic medical centers and universities or nonprofits. Industry partnerships are encouraged.
How to Apply: Deadlines for proposal submissions occur three times per year. Applications are reviewed in a two-step process: Letters of Intent (LOIs) are the first step, and should be submitted on the ADDF Funding Portal. ADDF’s science team will evaluate LOIs to determine whether the proposed project is consistent with the ADDF's mission and funding priorities. LOI decisions will be sent within three weeks of submission. Step 2 is an invited full proposal, which should include a detailed project narrative, budget and justification, and biographical information. When formulating the budget, note that the following costs are not covered: Indirect costs/Overhead, Publication costs, Equipment, and Travel.
Winter Deadlines: 04-February-2022 (LOI)
08-April-2022
(full proposal, by invitation)
Summer Deadlines: 20-May-2022 (LOI)
22-July-2022
(full proposal, by invitation)
Autumn Deadlines: 30-September-2022 (LOI)
02-December-2022
(full proposal, by invitation)
Further information
Specifically, the Drug Development RFP supports the following stages of discovery:
- Preclinical pharmacokinetics (PK) and pharmacodynamics (PD) (primarily in wild-type animals to inform dose selection for in vivo efficacy studies), as well as preliminary rodent tolerability studies
- In vivo efficacy or proof-of-concept studies in animal models of disease or aging, with a focus on measures of direct and indirect markers of target engagement and downstream pharmacologic effects
Current target areas of interest include:
- Epigenetics
- Inflammation
- Mitochondria & metabolic function
- Neuroprotection
- Proteostasis
- Synaptic activity and neurotransmitters
- Vascular function
- Other mechanisms and modes of action related to the biology of aging (e.g. senescent cells)
- Other novel targets or pathways that are supported by compelling evidence demonstrating a rational biological connection to the disease process
Funding: max. $600,000
Duration: 1 year
Eligibility: Funding is open to researchers and clinicians worldwide at academic medical centers and universities or nonprofits. Industry partnerships are encouraged.
How to Apply: Deadlines for proposal submissions occur three times per year. Applications are reviewed in a two-step process: Letters of Intent (LOIs) are the first step, and should be submitted on the ADDF Funding Portal. ADDF’s science team will evaluate LOIs to determine whether the proposed project is consistent with the ADDF's mission and funding priorities. LOI decisions will be sent within three weeks of submission. Step 2 is an invited full proposal, which should include a detailed project narrative, budget and justification, and biographical information. When formulating the budget, note that the following costs are not covered: Indirect costs/Overhead, Publication costs, Equipment, and Travel.
Winter Deadlines: 04-February-2022 (LOI)
08-April-2022
(full proposal, by invitation)
Summer Deadlines: 20-May-2022 (LOI)
22-July-2022
(full proposal, by invitation)
Autumn Deadlines: 30-September-2022 (LOI)
02-December-2022
(full proposal, by invitation)
Further information
- More information about the program is available here
- Detailed application instructions are here
- The application portal can be found here
Practical information
- General public
- Free